FocalTherics (NASDAQ:FOCL) Stock Rated “Hold” by Sell-Side Brokerages

FocalTherics (NASDAQ:FOCL) has been assigned an average recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $7.75.

Several brokerages have recently commented on FOCL. Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. Piper Sandler reiterated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research report on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a report on Tuesday, August 25th. Finally, Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th.

FocalTherics Price Performance

Shares of FOCL opened at $4.20 on Friday. The firm has a market cap of $157.63 million, a P/E ratio of -4.08 and a beta of -0.06. FocalTherics has a one year low of $1.75 and a one year high of $6.40. The stock has a 50 day simple moving average of $4.76. The company has a quick ratio of 1.38, a current ratio of 1.60 and a debt-to-equity ratio of 1.79.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 248.00%. The business had revenue of $13.20 million for the quarter. On average, sell-side analysts anticipate that FocalTherics will post -0.82 EPS for the current fiscal year.

Insider Buying and Selling at FocalTherics

In related news, Director David Horn purchased 10,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were acquired at an average cost of $4.75 per share, with a total value of $47,500.00. Following the completion of the purchase, the director directly owned 10,000 shares of the company’s stock, valued at $47,500. This trade represents a ? increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ryan Rhodes purchased 21,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was bought at an average cost of $4.75 per share, with a total value of $99,750.00. Following the acquisition, the chief executive officer owned 626,649 shares of the company’s stock, valued at $2,976,582.75. This represents a 3.47% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 116,000 shares of company stock valued at $551,000 over the last three months. Insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On FocalTherics

Hedge funds and other institutional investors have recently made changes to their positions in the company. SmartHarvest Portfolios LLC bought a new stake in shares of FocalTherics during the first quarter worth $38,000. Lido Advisors LLC bought a new position in FocalTherics in the first quarter valued at about $40,000. Flax Pond Capital LLC acquired a new stake in FocalTherics in the fourth quarter worth about $2,623,000. Finally, Rock Springs Capital Management LP increased its position in FocalTherics by 7.1% in the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after purchasing an additional 91,500 shares during the period. 62.74% of the stock is owned by institutional investors and hedge funds.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.